Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SVRA with free AI briefings, catalyst countdowns, and dilution alerts.

SVRA · Savara Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$129.6M Cash on Hand
10.8mo Cash Runway
Follow SVRA by email Get an email when SVRA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SVRA, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Molgramostim Autoimmune Pulmonary Alveolar Proteinosis Phase 3 · NCT06431776 Recruiting
Molgramostim Open-label Autoimmune Pulmonary Alveolar Proteinosis Phase 3 · NCT04544293 Active not recruiting
Vancomycin inhalation powder MRSA Phase 3 · NCT03181932 Completed
Antimycobacterial regimen Mycobacterium Infections, Nontuberculous Phase 2 · NCT03421743 Completed
Inhaled molgramostim Mycobacterium Infections, Nontuberculous Phase 2 · NCT03421743 Completed
Molgramostim nebulizer solution Mycobacterium Infections, Nontuberculous Phase 2 · NCT03597347 Terminated
Vancomycin hydrochloride inhalation powder Cystic Fibrosis Phase 2 · NCT01746095 Completed
AeroVanc Healthy Phase 1 · NCT01537666 Completed
IV vancomycin hydrochloride Healthy Phase 1 · NCT01537666 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SVRA holds $129.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $36.1M/quarter from operations, an estimated runway of 10.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SVRA files for a raise →

👥 Who Owns SVRA

Insiders 3.1% Other 5%+ holders 40.9% Institutions (237 holders) 56% Public and other holders 0%
HolderTypeShares% of sharesAs of
Growth Equity Opportunities 17, LLC 5%+ holder (13D) 24,471,264 11.09% 2025-11-12
Venrock Healthcare Capital Partners III, 5%+ holder (13G) 20,881,288 9.46% 2025-12-31
Bain Capital Life Sciences Fund II, L.P. 5%+ holder (13D) 17,600,621 7.98% 2025-03-25
Dapice Joshua J. 5%+ holder (13G) 15,000,000 6.80% 2025-12-31
TCG Crossover GP I, LLC 5%+ holder (13G) 12,362,205 5.60% 2025-12-31
BlackRock, Inc. Institution (13G, 5%+) 10,957,322 4.97% 2025-12-31
David A Ramsay
Director
Insider 2,533,642 1.15% 2025-12-19
Matthew Pauls
CHIEF EXECUTIVE OFFICER, Director · +900,000 options
Insider 1,188,050 0.54% 2025-12-14
David L Lowrance
Chief Financial Officer · +233,750 options
Insider 536,032 0.24% 2026-06-22
Kathleen R. McCabe
Chief Legal Officer
Insider 519,232 0.24% 2025-12-14
Anne Erickson
Chief Business Officer · +300,000 options
Insider 371,712 0.17% 2025-12-14
Raymond Dennis Pratt
Chief Medical Officer · +280,000 options
Insider 340,050 0.15% 2024-12-12

Share count 220,623,511 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SVRA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SVRA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.